Background Women with medical conditions associated with increased risk for thrombosis
generally should not use estrogen-containing contraceptives; however, less is known about …

The use of oral contraceptives (OC) is a well established risk factor for venous thrombosis. It
has been known for many years that almost all haemostatic parameters ie plasma levels of …

Background—Oral estrogen therapy increases the risk of venous thromboembolism (VTE) in
postmenopausal women. Transdermal estrogen may be safer. However, currently available …

Objective—Oral estrogen therapy increases venous thromboembolism risk among
postmenopausal women. Although recent data showed transdermal estrogens may be safe …

Recent publications describing the results of the Women's Health Initiative (WHI) and other
studies reporting the impact of hormone therapy on aging women have spurred …

Estrogen and progestins have been used by millions of women as effective combined
contraceptives. The safety of hormonal contraceptives has been documented by years of …

Since the early 1960s, it has been well documented that combined hormonal contraceptives
increase the risk of cardiovascular disease. Newer generation of oral formulations, as well …

The safety of combined hormonal contraceptives (CHCs) has been documented by years of
follow-up, and the occurrence of venous thromboembolism (VTE) possibly related to their …

Background: The risk of recurrent venous thrombosis is higher in men than in women, and
this is so far unexplained. We set out to determine the influence of age, time between first …

Use of oral contraceptives (OC) that combine a progestogen with synthetic ethinyl estradiol
(EE) is associated with increased risk of venous thromboembolism. NOMAC/E2 is a new …